Conjugated estrogens oral - Teva

Drug Profile

Conjugated estrogens oral - Teva

Alternative Names: Enjuvia; Synthetic conjugated estrogens, B - Barr Laboratories

Latest Information Update: 19 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Barr Laboratories
  • Developer Teva Womens Health
  • Class Estradiol congeners; Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Vasomotor symptoms

Most Recent Events

  • 18 May 2010 Efficacy data from a clinical trial in Vasomotor symptoms released by Teva Women's Health
  • 04 Oct 2007 Launched for Vaginal atrophy in USA (PO)
  • 30 Apr 2007 Registered as Enjuvia™ 0.9mg tablets for Vasomotor symptoms in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top